GlassScriptPhysician profile
Emilio E Castaneda
NPI 1194858746
$1,526.52
in general payments reported to CMS, 2019-2025
24 companies · $563 in 2025
The $563 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $51.30 · 2021: $209 · 2022: $159 · 2023: $132 · 2024: $241 · 2025: $563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $935.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $218.52 | 2021-2025 | Omnipod |
| Novo Nordisk INC | $199.61 | 2021-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $193.21 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.38 | 2023-2025 | Jardiance |
| Amarin Pharma, INC. | $109.12 | 2019 | |
| Xeris Pharmaceuticals, INC. | $90.53 | 2022-2025 | Gvoke Hypopen |
| Amgen INC. | $89.10 | 2021-2025 | Tepezza |
| Dexcom, INC. | $88.63 | 2023-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $62.65 | 2022-2025 | Freestyle Libre 3 |
| Ibsa Pharma INC. | $54.00 | 2021-2025 | Flector, Licart, Tirosint |
| Sanofi-Aventis U.S. LLC | $39.60 | 2020-2025 | |
| Allergan, INC. | $34.49 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $30.59 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $28.50 | 2022 | |
| Acella Pharmaceuticals, LLC | $28.21 | 2025 | NP Thyroid 60 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $24.83 | 2022 | |
| Corcept Therapeutics | $19.23 | 2024 | Korlym |
| Kvk-Tech, INC. | $17.04 | 2019 | |
| Abbvie INC. | $15.52 | 2025 | |
| Eisai INC. | $15.31 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.81 | 2023 | |
| Glaxosmithkline, LLC. | $14.68 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.96 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emilio Castaneda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.